AstraZeneca
Brennan bows to pressure and quits AstraZeneca
April 26, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, David Brennan, Q1, pharma
AstraZeneca’s chief executive David Brennan is to step down from his post following mounting dissatisfaction with his leadership. Brennan, who …
AstraZeneca diabetes drug recommended in Europe
April 23, 2012Sales and Marketing AstraZeneca, CHMP, FDA, Merck, WHO, diabetes
AstraZeneca and Bristol-Myers Squibb’s new type II diabetes treatment Forxiga has received a positive opinion by European regulators. The European …
AstraZeneca to buy Ardea for $1.3 billion
April 23, 2012Research and Development, Sales and Marketing Ardea, AstraZeneca, febuxostat, gout
AstraZeneca is to buy Ardea Biosciences for $1 billion to help bolster its pipeline. Under the terms of the agreement, …
Innovating in China’s pharma market
April 12, 2012Research and Development AstraZeneca, China, R&D, Steve Yang, emerging markets
The challenges that China and the wider Asia region face in healthcare represent big opportunities for multinational pharma companies. Cases of …
Investors ramp up pressure on AZ chief
April 10, 2012Sales and Marketing AstraZeneca, David Brennan
AstraZeneca’s chief executive David Brennan is coming under increasing pressure from investors, and his future at the firm could be …
The brain drain
April 5, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, R&D, brain drain, research and development
Concerns about the growing number of companies disinvesting from neuroscience research have been growing in recent years, and the latest …
AstraZeneca signs respiratory pact with Amgen
April 5, 2012Research and Development Amgen, AstraZeneca, MedImmune, respiratory
AstraZeneca has bought its way into Amgen’s inflammation portfolio with a $50 million upfront payment to co-develop and commercialise five …
AstraZeneca wins fresh US victory with Seroquel XR
April 2, 2012Sales and Marketing AZ, AstraZeneca, FDA, Seroquel XR
AstraZeneca is celebrating a US court verdict in its ongoing battle for intellectual property over the extended release version of …
High Court rules against Seroquel XR patent
March 23, 2012Sales and Marketing Accord, AstraZeneca, Sandoz, Seroquel, Teva
A British High Court has ruled that AstraZeneca’s patent on its new formulation of the antipsychotic Seroquel is invalid. Seroquel …
AstraZeneca pulls depression drug, takes $50m hit
March 20, 2012Research and Development, Sales and Marketing AstraZeneca, R&D, depression, failure, pipeline
AstraZeneca and partner Targacept will not file their depression drug TC-5214 for regulatory review. The decision comes after disappointing Phase …
AstraZeneca touting for business at partnering conference
March 19, 2012Research and Development, Sales and Marketing AstraZeneca, Bio-Europe, R&D, partnering
AstraZeneca is marketing itself as a key partner for drug development deals, ahead of a European partnering conference. The Bio-Europe …
AstraZeneca sues FDA over generic Seroquel
March 14, 2012Manufacturing and Production, Sales and Marketing AstraZeneca, FDA, Seroquel, US, generics
AstraZeneca has said it filed a lawsuit against the US FDA in a bid to block approval of generic versions …
AstraZeneca announces several non-executive moves
March 1, 2012Business Services, Manufacturing and Production, Research and Development, Sales and Marketing AstraZeneca, appointments
AstraZeneca has announced that Leif Johansson is set to be elected as a non-executive director in April, with the intention …
Caprelsa approved in Europe for thyroid cancer
February 21, 2012Sales and Marketing AstraZeneca, Caprelsa, FDA, RET, thyroid cancer
The European Commission has approved AstraZeneca’s thyroid cancer pill Caprelsa. Caprelsa (vandetanib) is now available in Europe for the treatment …
AstraZeneca to cut 7,300 jobs as growth stalls
February 2, 2012Business Services, Manufacturing and Production, Research and Development, Sales and Marketing AZ, AstraZeneca, David Brennan, R&D
AstraZeneca will make 7,300 cuts to its sales and R&D staff by 2014, but the company has not yet said …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
